ARCHIVES

Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

Peer Review changes Urged By NIH Team Include Appeals

April 8, 1977

How NCI’s Plans For Software Giveaway Sank In Scientific And Legal Disputes (Part Two In A Series About NCI’s Bioinformatics Venture caBIG).

March 4, 2011

Cancer Trials Take 800 Days To Start On Average; NCI Vows Improvement.

April 11, 2008

NCI-Approved Clinical Trials

August 31, 2001

NI Selects15 Cancer Patient Advocates for Director’s Consumer Liaison Group

November 23, 1997

Rep. Wyden Questions NCI Motive For Choosing Not To Pursue RU 486

September 4, 1992